{"filings":[{"id":554721,"accession_number":"0001104659-26-064518","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-05-20T20:15:36+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Gilead Sciences issues $3.0B in senior notes across four tranches (4.250%-4.900%)","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$500M 4.250% Senior Notes due 2028, $1B 4.400% due 2029, $1B 4.600% due 2031, $500M 4.900% due 2034.","Notes sold in public offering under Form S-3 shelf; proceeds for general corporate purposes incl. M&A.","Underwriting agreement dated May 14, 2026, with Barclays, BofA Securities, and Citigroup as reps."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99392,"accession_number":"0000882095-26-000022","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1 rev $7.0B (+4% YoY); raises FY rev guidance but slashes EPS guidance due to $11.5B charges","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Product sales ex-Veklury $6.8B (+8% YoY); HIV sales $5.0B (+10%); Biktarvy $3.4B (+7%).","GAAP diluted EPS $1.61 (vs $1.04); non-GAAP $2.03 (vs $1.81) — both up YoY.","Full-year product sales guidance raised to $30.0-30.4B; GAAP EPS guidance cut to $(3.25)-(2.85) from $6.75-7.15.","EPS guidance reduction driven by anticipated $11.5B IPR&D charges for Arcellx, Ouro and Tubulis acquisitions.","Cell Therapy sales down 12% to $407M; Trodelvy up 37% to $402M; Veklury down 52% to $144M."],"consensus_eps_estimate":null,"consensus_eps_actual":1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":6960000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99391,"accession_number":"0000882095-26-000008","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Gilead shareholders elect all nine directors, approve equity plan increase, reject three proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; Daniel O'Day received 980.6M votes for, 50.2M against.","Ernst & Young ratified as auditor for FY 2026: 1,046.4M for, 82.8M against, 1.0M abstain.","Say-on-pay approved with 954.3M for (92.6% of votes cast excluding broker non-votes).","Amended 2022 Equity Incentive Plan approved, adding 47.75M new shares to the pool.","Shareholder proposals on independent chair, patent exclusivity, and ESG metrics all defeated by wide margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":99390,"accession_number":"0001104659-26-049874","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-04-28T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Gilead completes $7.8B acquisition of Arcellx; adds anito-cel CAR T therapy for multiple myeloma","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price $115/share cash plus $5 CVR (contingent on $6B anito-cel sales by end-2029); total implied equity ~$7.8B.","Tender offer accepted 38.8M shares (~77.2% of outstanding); merger completed April 28, 2026.","Expected EPS dilution of ~$5.57-$5.67 in 2026; ex-R&D, modestly dilutive 2026-27, accretive from 2028.","Full control of anito-cel eliminates profit-sharing/royalty obligations; accelerates development and commercial launch.","Arcellx becomes wholly owned subsidiary of Gilead; ACLX common stock to be delisted from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115361,"accession_number":"0001104659-26-018314","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Gilead to acquire Arcellx for $115/share plus $5 CVR; implied equity value $7.8B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["$115 per share cash at closing plus one contingent value right of $5 per share; total implied equity value ~$7.8B.","CVR pays $5 if cumulative worldwide sales of anito-cel exceed $6B by Dec 31, 2029.","FDA accepted BLA for anito-cel in relapsed/refractory multiple myeloma; PDUFA date Dec 23, 2026.","Transaction expected to close Q2 2026; requires majority tender, regulatory approvals, and customary conditions.","Gilead currently owns ~11.5% of Arcellx; deal builds on existing Kite collaboration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":115360,"accession_number":"0000882095-26-000003","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2026-02-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q4/FY2025: revenue up 5% to $7.9B Q4, full-year EPS $6.78; guides 2026 sales $29.6-30B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 GAAP diluted EPS $1.74 vs $1.42 YoY; non-GAAP diluted EPS $1.86 vs $1.90.","Q4 product sales up 5% to $7.9B; HIV sales up 6% to $5.8B; Biktarvy $4.0B (+5%).","Full year 2025 total revenues $29.4B (+2%); product sales ex-Veklury $28.0B (+4%).","Full year GAAP diluted EPS $6.78 vs $0.38; non-GAAP $8.15 vs $4.62.","FY2026 guidance: product sales $29.6-30B, non-GAAP diluted EPS $8.45-8.85."],"consensus_eps_estimate":null,"consensus_eps_actual":6.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":29443000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131767,"accession_number":"0001104659-25-113968","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead Sciences EVP & General Counsel Deborah Telman to depart Dec 5, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Deborah H. Telman will step down as EVP, Corporate Affairs and General Counsel effective December 5, 2025.","Her employment with Gilead will terminate later in December.","No successor or interim arrangement has been announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131766,"accession_number":"0000882095-25-000044","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q3 2025: Non-GAAP EPS $2.47 beats $2.02; product sales ex-Veklury up 4% to $7.1B; guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $2.43 vs $1.00; non-GAAP EPS $2.47 vs $2.02; revenue $7.8B up 3% YoY.","Biktarvy sales up 6% to $3.7B; Descovy up 20% to $701M; HIV portfolio up 4% to $5.3B.","Veklury down 60% to $277M; Cell therapy down 11% to $432M; Trodelvy up 7% to $357M.","Full-year product sales guidance raised to $28.4-28.7B; non-GAAP EPS raised to $8.05-8.25.","Operating cash flow $4.1B; dividends $1.0B; share repurchases $435M in Q3."],"consensus_eps_estimate":null,"consensus_eps_actual":5.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":21518000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":131765,"accession_number":"0000882095-25-000041","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-10-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Gilead settles Biktarvy patent litigations; no generic entry expected before April 1, 2036","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlements with Lupin, Cipla, and Laurus Labs resolve patent disputes over generic Biktarvy.","No generic version of Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) permitted in US before April 1, 2036.","Agreements are subject to standard acceleration provisions.","Biktarvy is Gilead's leading HIV treatment; extending exclusivity protects significant revenue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148360,"accession_number":"0000882095-25-000035","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead names Erin Burkhart as SVP, Controllership and principal accounting officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Erin Burkhart, formerly Group VP and CAO at BioMarin, appointed effective September 22, 2025.","Burkhart succeeds Diane E. Wilfong, who steps down as interim Controller and principal accounting officer on the same date.","Burkhart previously held accounting/finance roles at Eli Lilly and began career at Arthur Andersen and Deloitte."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148359,"accession_number":"0000882095-25-000030","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2: revenue $7.1B, Biktarvy +9%, product sales ex-Veklury +4%; FY guidance raised","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $7.1B (+2% YoY), product sales ex-Veklury $6.9B (+4%); Biktarvy $3.5B (+9%).","GAAP diluted EPS $1.56 vs $1.29 YoY; non-GAAP diluted EPS $2.01, flat YoY.","FY2025 guidance raised: product sales $28.3-28.7B, diluted EPS $5.85-6.15, non-GAAP EPS $7.95-8.25.","HIV sales +7% to $5.1B; Trodelvy +14% to $364M; Cell therapy -7% to $485M.","FDA approved Yeztugo as first twice-yearly HIV prevention; MYR impairment $190M."],"consensus_eps_estimate":null,"consensus_eps_actual":2.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":13749000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":148358,"accession_number":"0000882095-25-000022","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-08-04T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Gilead amends bylaws to revise advance notice, proxy rules, and governance provisions","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Revised advance notice requirements for director nominations and stockholder proposals, including enhanced disclosure and universal proxy compliance.","Reserved white proxy card for exclusive use of the company; updates majority vote and board vacancy provisions.","Conformed stockholder meeting notice and list provisions to recent Delaware General Corporation Law amendments.","Added emergency governance provisions under DGCL Section 110; other clarifying and administrative changes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167135,"accession_number":"0000882095-25-000015","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Gilead annual meeting: all directors elected, say-on-pay approved, 4 proposals defeated","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All nine director nominees elected; CEO Daniel P. O'Day received 953.6M votes for (93.8% support).","Advisory say-on-pay approved with 929.6M for votes, ~90.9% of cast excluding broker non-votes.","Ratification of Ernst & Young as auditor for 2025 passed with 1.04B votes for (93.0%).","Four stockholder proposals (CEO pay ratio factor, independent chair, human rights policy, DEI contractor risks) all defeated.","Broker non-votes accounted for ~100M shares on director elections and say-on-pay."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":167134,"accession_number":"0000882095-25-000009","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1 revenue flat at $6.7B; GAAP EPS $1.04 vs -$3.34; cuts GAAP EPS guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $6.7B unchanged YoY; product sales ex-Veklury up 4% to $6.3B.","GAAP diluted EPS $1.04 vs $(3.34) in Q1 2024; non-GAAP diluted EPS $1.81 vs $(1.32).","Biktarvy sales $3.1B (+7% YoY); HIV product sales up 6% to $4.6B.","Full-year GAAP diluted EPS guidance cut to $5.65-$6.05 from $5.95-$6.35; product sales unchanged.","Cash $7.9B; operating cash flow $1.8B; $1.0B dividends, $730M buyback in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":6667000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184496,"accession_number":"0001104659-25-023012","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Gilead CAO Sandra Patterson departs; Diane Wilfong appointed interim CAO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Sandra Patterson, SVP, Corporate Controller and CAO, is leaving the company.","Diane E. Wilfong appointed interim Corporate Controller and CAO, effective March 12, 2025.","Wilfong previously served as Gilead's Corporate Controller and CAO from Feb 2016 to Mar 2023.","Wilfong, 63, also held similar roles at Computer Sciences Corp, Caesars Entertainment, and Eastman Kodak.","Company will conduct a search for a permanent successor; no departure reason provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":184495,"accession_number":"0000882095-25-000003","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q4 revenue up 6% to $7.6B; full year EPS hit by $4.2B impairment","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 product sales ex-Veklury +13% to $7.2B; HIV sales +16% to $5.5B, Biktarvy +21% to $3.8B.","Full year 2024 diluted EPS $0.38 vs $4.50, reflecting $4.2B Immunomedics IPR&D impairment and $3.9B CymaBay charge.","Non-GAAP diluted EPS Q4 $1.90 (+10%); full year $4.62 vs $6.72; cash, equivalents & securities $10.0B.","FY2025 guidance: product sales $28.2-28.6B; non-GAAP EPS $7.70-8.10; Veklury sales expected $1.4B.","Issued $3.5B senior notes in Q4; paid $973M dividends and repurchased $350M stock."],"consensus_eps_estimate":null,"consensus_eps_actual":0.38,"consensus_revenue_estimate":null,"consensus_revenue_actual":28754000000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201082,"accession_number":"0001104659-24-128088","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K/A","filed_at":"2024-12-13T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gilead appoints Dietmar Berger as Chief Medical Officer effective Jan 2, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dietmar Berger, MD PhD, will become Chief Medical Officer and member of senior leadership team on January 2, 2025.","Berger succeeds Merdad Parsey, MD PhD, who will stay as Senior Advisor through Q1 2025.","Berger previously served as Chief Medical Officer and Global Head of Development at Sanofi.","Berger will oversee Gilead's virology, oncology, inflammation portfolio and global Development/Medical Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201084,"accession_number":"0001104659-24-121025","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-11-20T23:59:59+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Gilead issues $3.5B in senior notes across four tranches with maturities 2029-2064","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $750M 4.80% Senior Notes due 2029, $1B 5.10% due 2035, $1B 5.50% due 2054, $750M 5.60% due 2064.","Net proceeds to be used for general corporate purposes, including possible repayment of indebtedness.","Underwriting agreement with Barclays Capital Inc. and BofA Securities, Inc. dated November 13, 2024.","Notes sold under existing shelf registration statement; supplemental indenture entered November 20, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":201083,"accession_number":"0000882095-24-000025","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q3 revenue up 7% to $7.5B; raises full-year guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $1.00 (down from $1.73) due to $1.75B Immunomedics IPR&D impairment; Non-GAAP EPS $2.02 vs $2.29.","Biktarvy sales $3.5B (+13% YoY); HIV product sales $5.1B (+9%); Trodelvy $332M (+17%).","Full-year product sales guidance raised to $27.8-28.1B (from $27.1-27.5B); Non-GAAP EPS raised to $4.25-4.45 from $3.60-3.90.","Operating cash flow $4.3B in Q3; paid $983M dividends and repurchased $300M stock.","Oncology sales $816M (+6%); Cell therapy sales $485M flat YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":21185000000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217105,"accession_number":"0000882095-24-000020","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q2 revenue $7.0B (+5%), Non-GAAP EPS $2.01; raised Non-GAAP FY guidance to $3.60-$3.90","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 revenue $7.0B (+5% YoY); GAAP diluted EPS $1.29 (prior $0.83), Non-GAAP diluted EPS $2.01 (prior $1.34).","HIV sales +3% to $4.7B; Biktarvy sales +8% to $3.2B; Oncology +15% to $841M; Trodelvy +23% to $320M.","Full-year 2024 product sales guidance unchanged at $27.1-27.5B; non-GAAP EPS guidance raised to $3.60-$3.90; GAAP EPS lowered to $0.00-$0.30.","Phase 3 lenacapavir for HIV prevention showed 100% efficacy in cisgender women; CymaBay acquisition closed for $3.9B.","Product gross margin 77.7% GAAP, 86.0% non-GAAP; operating cash flow $1.3B after $1.2B transition tax payment."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":13640000000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":217104,"accession_number":"0001104659-24-080355","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-07-17T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Gilead CMO Merdad Parsey to depart early 2025; successor search begins","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Chief Medical Officer Merdad Parsey, M.D., Ph.D., will leave Gilead early next year.","Parsey will remain CMO until Q1 2025 to assist with transition while successor is identified.","He joined Gilead in November 2019 and oversaw expansion of pipeline to 54 ongoing clinical trials.","CEO Daniel O'Day praised Parsey's role in doubling the portfolio and advancing virology, oncology, and inflammation.","No formal departure date; transition expected through Q1 2025 or as mutually agreed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236870,"accession_number":"0000882095-24-000016","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Gilead stockholders approve officer exculpation amendment, elect directors, pass say-on-pay","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Officer exculpation amendment approved with 905.5M for, 101.7M against (85.6% support).","All nine director nominees elected; CEO Daniel O'Day received 939.1M for, 63.1M against.","Advisory say-on-pay passed with 928.7M for, 78.6M against (91.7% of votes cast).","Ernst & Young ratified as auditor with 1.04B for, 74.1M against.","Three stockholder proposals (employee board seat, abortion risk report, equity retention) all defeated by wide margins."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":236869,"accession_number":"0000882095-24-000010","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Gilead Q1 GAAP loss per share $(3.34) on $3.9B CymaBay charge; guidance slashed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS loss $(3.34) vs $0.80 YoY; non-GAAP loss $(1.32) vs $1.37.","Revenue up 5% to $6.7B; base business ex-Veklury up 6% to $6.1B.","Biktarvy up 10% to $2.9B; Oncology up 18% to $789M.","Full-year GAAP EPS guidance cut to $0.10–$0.50 from $5.15–$5.55; non-GAAP to $3.45–$3.85 from $6.85–$7.25.","Cash $4.7B; operating cash flow $2.2B; dividends paid $990M; $400M stock buyback."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":6686000000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":254481,"accession_number":"0001104659-24-037619","cik":882095,"company_name":"GILEAD SCIENCES, INC.","ticker":"GILD","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["7.01","9.01","8.01"],"status":"ready","headline":"Gilead completes $4.3B acquisition of CymaBay; seladelpar added to liver pipeline","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Total equity value ~$4.3 billion; Gilead paid $32.50 per CymaBay share.","Tender offer resulted in 77.3% of shares tendered (93.7M shares); remaining shares converted at same price.","CymaBay becomes wholly owned subsidiary; CBAY to be delisted from Nasdaq on March 22, 2024.","Transaction expected to reduce Gilead's 2024 GAAP/non-GAAP EPS by $3.10-$3.20; including costs, $3.35-$3.45 relative to prior guidance.","Seladelpar (for primary biliary cholangitis) is key asset; safety/efficacy not yet established."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":165985464496.61798,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}